We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+14.58%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$865M
AUM Growth
+$9.54M
(+1.1%)
Cap. Flow
-$78.4M
Cap. Flow
% of AUM
-9.07%
Top 10 Holdings %
Top 10 Hldgs %
8.56%
Holding
892
New
315
Increased
150
Reduced
128
Closed
299
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XP
XP
|
+$7.27M |
| 2 |
Constellation Brands
STZ
|
+$7.01M |
| 3 |
Eli Lilly
LLY
|
+$6.9M |
| 4 |
Automatic Data Processing
ADP
|
+$6.79M |
| 5 |
Nu Holdings
NU
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$11.9M |
| 3 |
Microsoft
MSFT
|
+$11.8M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$11.7M |
| 5 |
Las Vegas Sands
LVS
|
+$11.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.67% |
| 2 | Healthcare | 18.49% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Industrials | 10.31% |
| 5 | Financials | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Belden
BDC
$5.03B
| $931K | 0.11% |
+12,053
| New | +$896K |
|
277
Bio-Rad Laboratories Class A
BIO
$8.93B
| $921K | 0.11% |
2,852
+675
| +31% | +$212K |
|
278
Dick's Sporting Goods
DKS
$18B
| $913K | 0.11% |
6,211
-5,469
| -47% | -$665K |
|
279
Norfolk Southern
NSC
$76.4B
| $912K | 0.11% |
3,860
+1,802
| +88% | +$378K |
|
280
FMC
FMC
$1.3B
| $912K | 0.11% |
14,464
+6,861
| +90% | +$398K |
|
281
Zions Bancorporation
ZION
$10.6B
| $907K | 0.11% |
+20,684
| New | +$747K |
|
282
Ameriprise Financial
AMP
$49.1B
| $906K | 0.1% |
2,386
-1,255
| -34% | -$430K |
|
283
Fox Factory Holding Corp
FOXF
$827M
| $906K | 0.1% |
+13,421
| New | +$979K |
|
|
BECN
284
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $893K | 0.1% |
10,266
+3,044
| +42% | +$239K |
|
285
EnerSys
ENS
$7.12B
| $893K | 0.1% |
+8,847
| New | +$813K |
|
286
CBRE Group
CBRE
$43.3B
| $892K | 0.1% |
9,580
+4,822
| +101% | +$375K |
|
287
Academy Sports + Outdoors
ASO
$3.03B
| $890K | 0.1% |
+13,485
| New | +$684K |
|
288
Jabil
JBL
$36.2B
| $886K | 0.1% |
6,956
-62,147
| -90% | -$7.91M |
|
289
Xerox
XRX
$430M
| $883K | 0.1% |
+48,153
| New | +$712K |
|
290
Grand Canyon Education
LOPE
$3.92B
| $883K | 0.1% |
+6,684
| New | +$870K |
|
291
Conagra Brands
CAG
$7.18B
| $880K | 0.1% |
+30,694
| New | +$860K |
|
292
Advance Auto Parts
AAP
$3.51B
| $878K | 0.1% |
+14,379
| New | +$787K |
|
293
Parker-Hannifin
PH
$126B
| $875K | 0.1% |
+1,899
| New | +$791K |
|
294
United Microelectronic
UMC
$52.2B
| $874K | 0.1% |
+103,252
| New | +$787K |
|
295
Copa Holdings
CPA
$6.03B
| $873K | 0.1% |
+8,213
| New | +$751K |
|
296
JetBlue
JBLU
$2.45B
| $869K | 0.1% |
+156,524
| New | +$733K |
|
297
Peloton Interactive
PTON
$2.85B
| $855K | 0.1% |
+140,455
| New | +$757K |
|
298
Westlake Corp
WLK
$10.1B
| $854K | 0.1% |
+6,103
| New | +$775K |
|
299
SM Energy
SM
$7.55B
| $852K | 0.1% |
+21,992
| New | +$848K |
|
|
ETRN
300
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $842K | 0.1% |
82,746
+10,020
| +14% | +$94.3K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Seven Eight Capital held 892 positions worth $865M, up 1.1% from $855M the previous quarter. Its ten largest holdings account for 8.6% of the portfolio.
Seven Eight Capital withdrew a net $78.4M in Q4 2023, closing 299 positions and reducing 128 holdings. Its most notable exit was Merck, an estimated $11.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Seven Eight Capital opened a new position in XP worth $8.3M.
- Seven Eight Capital's largest Q4 2023 buy was XP: 318,542 shares worth $8.3M.
- Seven Eight Capital added most to Constellation Brands in Q4 2023, an estimated $7.01M increase.
- Seven Eight Capital's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $11.9M.
- Seven Eight Capital fully exited Merck in Q4 2023, selling an estimated $11.9M.
- Seven Eight Capital's ten largest holdings make up 8.6% of its $865M portfolio in Q4 2023.
- Seven Eight Capital opened 315 new positions and closed 299 in Q4 2023.
- Seven Eight Capital's portfolio value rose 1.1% quarter-over-quarter to $865M.
Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.